Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis

Table 5

Summary of studies on early chronic suppressive therapy of MSSA.

Author	Study design	Subjects	Drug used	Outcomes	Main results
Loening-Baucke et al. [26]	RCT	𝑁=17.; Age = infants and children.; Inclusion criteria: CF diagnosis	Cephalexin	Clinical and microbiological	Significant improvement in clinical and microbiological parameters
Weaver et al. [27]	RCT	𝑁=38.; Age = 7 weeks (prophylaxis group), 5 weeks for (as required group).; Inclusion criteria: CF diagnosis	Oral flucloxacillin 250 mg/day up to 2 years	Clinical and microbiological parameters, hospital admissions	More cough, greater numbers of S aureus isolates and increased hospitalization in the other (as required) group
Nolan et al. [28]	Prospective study	𝑁=47.; Age = children.; Inclusion criteria: mild to moderate CF	Inhaled cephaloridine and oral cloxacillin in one group. Only oral cloxacillin in other groups	Number of respiratory tract infections or hospital admissions and change of pulmonary function	Haemophilus influenzae carriage was greater in the group not receiving inhaled antibiotic. High rates of carriage of P. aeruginosa and P. cepacia in both the groups
Ratjen et al. [29]	Prospective study	𝑁=639.; Age = <18 year.; Inclusion criteria: P. aeruginosa negative prior to entry and at least 2 additional P. aeruginosa negative respiratory cultures while being followed up	48.2% received continuous prophylaxis, 40.4% received intermittent, and 11.4% received no prophylaxis with anti-staphylococcal antibiotics	Number of respiratory tract infections	Continuous prophylaxis group has a high rate of acquisition of P. aeruginosa than the other two groups
Stutman et al. [30]	Multicentre,; RCT	𝑁=119.; Age = <2 year; Inclusion criteria: CF diagnosis	Oral cephalexin 80–100 mg/kg/day up to 5–7 years	Clinical, microbiologic, laboratory, radiographic, and anthropometric outcomes	Except an increased isolation of P. aeruginosa, there were no other benefits